secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0000950170-24-029956
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical Q4 2023 net loss narrows to $4.8M; cash runway to Q3 2025
------------------------------------------------------------------------------

- Net loss Q4 2023 of $4.8M ($0.08/shr) improved from $9.7M loss ($0.16/shr) in Q4 2022.
- License revenue Q4 2023 of $6.3M, up from $0.3M, driven by $5M BioCryst upfront and $1M Aura milestone.
- Cash $28.9M at Dec 31; subsequent $15M equity offering extends runway into Q3 2025.
- Phase 2b ODYSSEY wet AMD trial topline data expected Q3 2024; randomization completed Dec 2023.
- Full year 2023 net loss $32.5M ($0.53/shr) vs $32.9M ($0.55/shr) in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017024029956/0000950170-24-029956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017024029956/clsd-20240312.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer